

CURRICULUM VITAE

Date of Revision: July 6, 2021
Name: Jennifer Lynn Sherr, MD, PhD
School: Yale University School of Medicine

Education:

B.A. Rutgers College (Major: Biology; Minor: English) Graduated with honors, 2000
M.D. UMDNJ-Robert Wood Johnson Medical School- joint BA/MD program between Rutgers University and UMDNJ-RWJMS, 2003
Ph.D. Yale University Graduate School of Arts & Sciences (Investigative Medicine), 2011

Career/Academic Appointments:

2003-06 Pediatric Resident, Yale-New Haven Children's Hospital, New Haven, CT
2006-11 Postdoctoral Fellow in Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT
2011-14 Instructor, Department of Pediatrics, Yale University School of Medicine, New Haven, CT
2014-2017 Assistant Professor, Department of Pediatrics, Yale University School of Medicine, New Haven, CT
2017-present Associate Professor, Department of Pediatrics, Yale University School of Medicine, New Haven, CT

Administrative Positions:

2007-10 Teaching Assistant - Investigative Medicine Seminars in Clinical Investigation through the Yale Investigative Medicine Program, Yale Graduate School of Arts and Sciences
2008-10 Teaching Assistant - Investigative Medicine Principles of Clinical Research through the Yale Investigative Medicine Program, Yale Graduate School of Arts and Sciences

Board Certification:

American Board of Pediatrics, Pediatric Endocrinology, 2011

Professional Honors & Recognition:

International / National / Regional

2021: CHF Macy Nigh-Whitener Visiting Professorship at Oklahoma University Health
2016: Selected as the Junior Faculty Member in Pediatrics for the Type 1 Diabetes Exchange Steering Committee
2015: Elected as a member of Society for Pediatric Research
2013: American Society for Clinical Investigation Young Physician-Scientist Award
2012: American Diabetes Association Young Investigator Travel Grant Award
2012: Translational Science Meeting/Scholar Abstract Award
2000: Recipient of UNICO National Dr. Benjamin Cottone Scholarship – given to a student as recognition for superior scholarship and outstanding leadership
2003: Inducted into the Arnold P. Gold Humanism Society

- 2002: Recipient of Executive Women of New Jersey Scholarship
- 1997: Recipient of Eli Lilly for Learning Diabetes Scholarship
- 1996: Edward J. Bloustein Distinguished Scholar
- 1995: Designated a Young Woman of Excellence by the Middlesex County Commission on the Status of Women

University

- 2016: Recipient of Mae Gailani Award, which “honors that individual who personifies the remarkable spirit of Mae Gailani, an exceptional neonatologist, young investigator, teacher and citizen in the department of Pediatrics.”
- 2003: UMDNJ-RWJMS Recipient of Alumni Award
- 2003: Recipient of Arnold P. Gold Foundation Humanism in Medicine Award
- 2003: Recipient of UMDNJ-RWJMS Community Service Award
- 2003: Recipient of UMDNJ-RWJMS Excellence in Pediatrics Award
- 2003: Recipient of UMDNJ-RWJMS Richard Harvey and Pamela Champe Award in Biochemistry
- 2002: Governor McGreevy’s Commission on Health Science Education and Training—chosen to serve as student representative for UMDNJ-RWJMS to commission
- 2000: Recipient of Van der Pol Merit Scholarship through Rutgers University
- 1999: Recipient of Rutgers College Class of 1924 Merit Scholarship
- 1999: Golden Key National Honors Society
- 1996: Member of Rutgers College General Honors Program

Grant/Clinical Trial History:

Current Grants

Agency: NIH/NIDDK

ID: 5U01DK123799-02

HIC #: 2000029893

Title: eMOM: enhanced Monitoring to Optimize Maternal diabetes detection

Role on project: Yale Principal Investigator

Percent effort: 20%

Total costs for project period: \$3,699,308

Project period: 9/20/19-7/31/24

Agency: JDRF / University of Minnesota Subaward

ID: N007829504

HIC #: 2000027284

Title: Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes: A Proof-of-Concept Study

Role on project: Yale Site Principal Investigator

Percent effort: 10%

Total costs for project period: \$392,515

Project period: 9/1/19-8/31/2021

Agency: NIH/NIDDK / University of South Florida Subaward

ID: 5U01DK106993-03

HIC #: 2000021339, 2000029217, 1208010654

Title: TrialNet Clinical Center

Role on project: Yale Site Principal Investigator

Percent effort: 10%

Total costs for project period: \$337,975

Project period: 7/1/21-6/30/2022 with anticipated annual renewal through 2024

Agency: NIMHD / NIH

ID: 1R01MD015974-01

Title: Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth

P.I.: Nicola Santora

Role on project: Co-Investigator

Percent effort: 5%

Total costs for project period: \$3,466,595

Project period: 4/1/21-1/31/26

Agency: Jaeb Health Center

ID: NA

HIC#: Pending

Title: Type 1 Diabetes EXercise Initiative Pediatric Study (T1DexiP): The Effect of Exercise on Glycemic Control in Youth with Type 1 Diabetes

Role on project: Site PI and Co-Chair

Percent Effort: 9%

Project Period: 1/1/2021-12/31/2022

Current Clinical Trials:

Agency: Insulet Corporation

ID: HIC # 2000028454

Title: Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort

Role on project: Yale Site Principal Investigator

Percent effort: 10%

Total costs for project periods: Per Subject Cost (Preschool + Extension): \$21,334

Project period: 8/10/20-6/18/21 (amendment for extension being executed)

Agency: Insulet Corporation

ID: HIC # 2000026690

Title: Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children with Type 1 Diabetes

Role on project: Yale Site Principal Investigator

Percent effort: 10%

Total costs for project period: Per Subject Cost (Pivotal + Extension): \$25,709

Project period: 10/1/19-11/26/21

Agency: Medtronic Diabetes

ID: HIC # 2000025419

Title: Safety and Effectiveness Evaluation of the Advanced Hybrid Closed Loop (AHCL) system in Adult and Adolescent Subjects with Type 1 Diabetes Study

Role on project: Yale Site Principal Investigator

Percent effort: 6%

Total costs for project period: Per Subject Cost (Study Phase): \$12,301

Project period: 7/16/19-4/26/24

Pending Grants:

Agency: NIH / Massachusetts General Hospital Subaward

ID: R01

Title: GoMoms A1C/CBC Ancillary

Role on project: Site PI

Percent Effort: 3%

Total costs for project period: \$187,230

Project period: 4/1/21-3/31/26

Agency: NIH / Brigham and Women's Hospital Subaward

ID: R01

Title: Glycemic Observation in Babies (GoBabies)

Role on project: Site PI

Percent Effort: 5%

Total costs for project period: \$734,933

Project period: 4/1/21-3/31/26

Agency: NIH

ID: R01

Title: Enhanced glucose Monitoring to improve Pregnancy Outcomes for Women Requiring medications for gestational diabetes (EMPOWR)

Role on project: Co-investigator

Percent Effort: 10%

Total costs for project period: \$4,132,395

Project period: 12/01/2021 – 11/30/2026

Agency: JDRF

ID: Advanced Postdoctoral Fellowship

Title: Metabolic phenotyping of early islet autoimmunity: longitudinal trajectory of incretin effect, insulin sensitivity, and beta cell function

Role on project: Mentor

Percent Effort: 10%

Total costs for project period: \$285,000

Project period: 6/30/2022-6/30/2025

Past Grants:

Agency: Insulet Corporation

ID: HIC # 2000021293

Title: Evaluating glucose control in patients with type 1 diabetes under free-living conditions with the Insulet automated glucose control system: IDE3

Role on project: Yale Site Principal Investigator

Percent Effort: 15%

Total costs for project period: Study Start up costs: 4,658.42, \$11,893/patient. Recruitment goal 15 subjects

Project period: 7/1/2017-6/30/2021

Agency: Juvenile Diabetes Research Foundation

ID: 2-SRA-2020-884-M-B

HIC # 2000025170

Title: Pathogenesis of the cardiometabolic risk in youth with T1D
Role on project: Yale Co-Principal Investigator
Percent Effort: 10%
Total costs for project period: \$225,398
Project Period: 11/1/2019-10/31/2020

Agency: Jaeb Health Center
ID: HIC # 2000021899
Title: CGM Intervention in Teens and Young Adults with T1D (CITY) or CITY T1D
Role on project: Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period: \$TBD
Project period: 10/1/2017-12/30/2019

Agency: Juvenile Diabetes Research Foundation
ID: 5-ECR-2014-112-A-N
Title: Clinical Strategies to improve Closed-loop system performance
Role on project: P.I.: Jennifer Sherr
Percent effort: 45%
Total costs for project period: \$749,997
Project period: 7/1/2014-6/30/2019

Agency: Xeris Pharmaceuticals/The Emmes Corporation
ID: HIC # 1603017392
Title: A phase 3B study to evaluate the glucose response of the g-pen (glucagon injection) in pediatric patients with type 1 diabetes
Role on project: Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period: Payment based on subject age (2<6 years: \$8,000/patient; 6<12 years \$7,500/patient; 12<18 years \$12,400/patient)
Project period: 3/1/2017-12/31/2017

Agency: Jaeb Health Center
ID: HIC # 2000021082
Title: A Study to Assess Continuous Glucose Sensor Profiles in Healthy Non-Diabetic Subjects
Role on project: Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period: Certification \$7,500 and \$500 per participant

Agency: Medtronic Diabetes
ID: HIC # 1404013744
Title: Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature with a Sensor-Augmented Pump System in Pediatric Patients with Type 1 Diabetes (CEP287)
Role on project: Yale Site Principal Investigator
Percent effort: 5%
Total costs for project period: \$3,040 per patient
Project period: 7/1/2014-6/30/2017

Agency: Jaeb Health Center
ID: HIC # 1505015837

Title: Beta Cell Function and Glucose counter-regulation during the progression of Type 1 Diabetes

Role on project: Yale Site Principal Investigator

Percent effort: 5%

Total costs for project period: \$1,957 per patient

Project period: 8/1/2015-8/31/2016

Agency: Medtronic Diabetes

ID: HIC # 1403013588

Title: A Performance Evaluation of the Enlite and Enlite 2 Glucose Sensor to Support a Full 144 hours (6 Days) of Use in Children CEP249

Role on project: Yale Site Principal Investigator

Percent effort: 5%

Total costs for project period: \$11,050 per patient

Project period: 7/1/2015-12/31/2016

Agency: Jaeb Health Center

ID: HIC # 1505015938

Title: Mini-Dose glucagon for Adults with Type 1 Diabetes: A pilot Study to Assess the Efficacy and Safety of Mini-Dose Glucagon for Treatment of Non-Severe Hypoglycemia in Adults with Type 1 Diabetes

Role on project: Yale Site Principal Investigator

Percent effort: 5%

Total costs for project period: \$1,900 per patient

Project period: 8/1/2015-3/31/2016

Agency: Juvenile Diabetes Research Foundation

ID:17-2013-5

Title: Effect of Liraglutide on automated closed loop glucose control in type 1 diabetes

P.I.: Jennifer Sherr

Percent effort: 30%

Total costs per project period: \$403,912

Project period: 2/1/2013-4/15/2015

Agency: Jaeb Health Center

ID: HIC #1307012428

Title: Assessment of Intranasal Glucagon in Children and Adolescents with Type 1 Diabetes

Role on project: Yale Site Principal Investigator

Percent effort: 5%

Total costs for project period: \$7,190 per patient

Project period: 8/1/2013-12/31/2014

Agency: Jaeb Health Center

ID: HIC # 1307012447

Title: Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults with Diabetes

Role on project: Yale Site Principal Investigator

Percent effort: 5%

Total costs for project period: \$7,240 per patient

Project period: 8/1/2013-12/31/2014

Agency: NIH-NIDDK
ID: 1 K12 DK094714-01
Title: Pediatric Endocrine/Diabetes Physician Scientists
P.I.: William Tamborlane
Role on project: Trainee
Percent effort: 75%
Project period: 12/1/11-11/30/16

Agency: Yale Center for Clinical Investigation
ID: YCCI Scholar Award
Title: Effect of Liraglutide on automated closed loop glucose control in type 1 diabetes
P.I.: Jennifer Sherr
Percent effort: 25%
Project period: 8/1/2011-6/30/2013

Agency: American Diabetes Association
ID: ADA-Merck Clinical/Translational Postdoctoral Fellowship Award
Title: Beta before alpha: The importance of residual beta-cell function for alpha-cell secretion of glucagon in response to hypoglycemia
P.I.: Kevan Herold
Role on project: Trainee
Percent effort: 75%
Project period: 7/1/2009-6/30/2011

Agency: Yale Center for Clinical Investigation
ID: Pilot Projects in Translational and Interdisciplinary Research
Title: Assessment of Residual Insulin Production and Its Association to Retention of Counterregulatory Responses to Hypoglycemia and Immune Markers in Patients with Long Standing Type 1 Diabetes
P.I.: Kevan Herold
Role on project: Sub-investigator
Percent effort: 25%
Project period: 2/1/11-1/31/2013

Agency: Lawson Wilkens Pediatric Endocrine Society
ID: Research Fellowship Award
Title: Beta before alpha: The importance of residual beta-cell function for alpha-cell secretion of glucagon in response to hypoglycemia
P.I.: Jennifer Sherr
Grant turned down as ADA-Merck Clinical/Translational Postdoctoral Fellowship Award was funded.

Agency: Helmsley Charitable Trust
Title: Effect of LX4211 on control to target automated insulin delivery
P.I: Jennifer Sherr
Percent effort: 30%
Total costs for project period: \$479,900
Project period: 11/1/2014-10/31/2017

Invited Speaking Engagements, Presentations, Symposia, and Workshops Not Affiliated with Yale

International/National

- 2021: Glucagon in the prevention and treatment of hypoglycemia. Invited Speaker at the American Diabetes Association Annual Scientific Sessions. June 2021. Virtual International Conference.
- 2021: Clinical Practice Guidelines: Use of Advanced Diabetes Technology in Management of Diabetes. Invited Speaker at the American Association of Clinical Endocrinology Annual Meeting. May 2021. Virtual National Meeting.
- 2021: Updates on Diabetes Technology. Moderator at the American Association of Clinical Endocrinology Annual Meeting. May 2021. Virtual National Meeting.
- 2021: Diabetes Technology Roundtable V: AID Systems Data Unleashed: Outcomes Insights Settings Simplicity. Moderator for cgmEducation.net May 2021 Virtual National Meeting.
- 2021: Closed Loop Systems Are Here; Are We Ready. Invited Speaker for the Pediatric Endocrine Society Annual Meeting. May 2021. Virtual National Meeting.
- 2021: Meet the Professor: Youth-Onset Type 2 Diabetes Mellitus. Moderator at the Endocrine Society Annual Meeting. March 2021. Virtual National Meeting.
- 2021: Managing the Sick Patient at Home. Invited Speaker for Endocrine Society's T1D Fellow's Conference. March 2021. Virtual National Meeting.
- 2021: Optimizing Management of T1D in Youth: From Closed Loop Insulin Delivery to Adjunctive Therapy.
- 2021: The Dawn of a New Era in Treatment: How Diabetes Technologies Holds the Promise to Transform Care. CHF Macy Nigh-Whitener Lecture Grand Rounds Presentation. Oklahoma University Health. January 2021 Regional Meeting.
- 2021: Diabetes Technology Roundtable IV: Novel Insulin Pumps and AID Systems. Invited Speaker for cgmEducation.net January 2021 Virtual National Meeting.
- 2020: The Minimed™ 780G system User's and HCP's experience. Invited Speaker International Society for Pediatric and Adolescent Diabetes Annual Meeting. October 2020. Virtual International Meeting.
- 2020: Overview of Treatments Recommended for Hypoglycemia. Invited Speaker for Forefront Collaborative. September 2020 Virtual National Meeting.
- 2020: Preparing Your Patient for Severe Hypoglycemia Rescue. Invited Speaker for the European Association for the Study of Diabetes Annual Meeting. September 2020. Virtual International Meeting.
- 2020: Adjunctive therapy for Type 1 Diabetes: Metformin and Pramlintide. Invited Speaker for the Advanced Diabetes Technologies & Treatments for Diabetes Annual Meeting. Madrid, Spain. February 2020
- 2020: Nasal Glucagon: a Novel Rescue Therapy for Severe Hypoglycemia. Invited Speaker for the Advanced Diabetes Technologies & Treatments for Diabetes Annual Meeting. Madrid, Spain. February 2020
- 2019: Diabetes Technology in Pediatrics. Keynote Speaker for The Hospital for Sick Children Toronto, Canada. November 2019.
- 2019: Managing the Sick Patient at Home. Invited Speaker for Endocrine Society's T1D Fellow's Conference. New Orleans. March 2019.
- 2019: Optimizing Multiple Daily Injection Therapy. Invited Speaker for Endocrine Society's T1D Fellow's Conference. New Orleans, LA. March 2019.
- 2019: Diabetes Technology in Pediatrics: ISPAD Guidelines Update and the Future- Insulin Pumps. Invited Speaker for the Advanced Diabetes Technologies & Treatments for Diabetes Annual Meeting. Berlin, Germany. February 2019
- 2018: Minimed 670G System: Integrating Smartguard Automode Into Your Practice. Invited Speaker at 21st Professional Conference & Annual Meeting of Diabetes Canada. Halifax, Canada. October 2018

- 2018: Closed Loop Systems for Type 1 Diabetes in Youth, Children are Not Just Small Adults. Invited Speaker at American Diabetes Association Annual Scientific Sessions. Orlando, Florida. June 2018.
- 2018: MiniMed 670G system- Increasing Time in Range with Automated Insulin Delivery. Invited Speaker at American Diabetes Association Annual Scientific Sessions. Orlando, Florida. June 2018.
- 2018: Panel Member: JDRF/NIH/HCT Closed Loop Research Meeting. What research areas have the most potential to attain fully closed-loop systems, in the foreseeable future and beyond? Orlando, Florida. June 2018.
- 2018: Beyond Insulin: Additional Hormones with Closed-Loop Systems. Invited Speaker Pediatric Academic Society Annual Meeting. Toronto, Canada. May 2018.
- 2018: Nasal Glucagon: An alternative innovative needle-free approach for the treatment of severe hypoglycemia. Invited Speaker at the Advanced Diabetes Technologies & Treatments for Diabetes Annual Meeting. Vienna, Austria. February 2018
- 2018: Practical Closed-Loop Therapy: The Patient Perspective. Invited Speaker at the Advanced Diabetes Technologies & Treatments for Diabetes Annual Meeting. Vienna, Austria. February 2018
- 2017: My Journey to Physician Scientist: Lessons learned and the rewarding side of research. Invited Speaker Juvenile Diabetes Research Foundation Training Grantees Workshop. New York, NY. November 2017
- 2017: Treatment of T1D in those with Suboptimal Glycemic Control. Invited Speaker at the Diabetes Technology Meeting. Washington, DC. November 2017
- 2017: Performance of the Medtronic 670G system. Invited Speaker at the Diabetes Technology Meeting. Washington, DC. November 2017
- 2017: Sensor Integrated Pump Therapy. Invited Speaker at 13th Annual Clinical Diabetes Technology Meeting. Houston, TX. April 2017.
- 2016: Artificial Pancreas Update. Invited Speaker at JDRF Metro Detroit Chapter Type One Nation Summit. Detroit, Michigan. November 2016
- 2016: Joint ADA/JDRF Symposium- Alternate Delivery Methods of Glucagon and Insulin in Pediatrics. Invited Speaker at the 76th Scientific Session of the American Diabetes Association. New Orleans, LA. June 2016.
- 2016: Seasonal Patterns in Glycemic Control. Invited Speaker at the Type 1 Diabetes Exchange Investigator meeting. Tampa, FL. March 2015.
- 2015: Assessment of Intranasal Glucagon in Children and Adolescents with Type 1 Diabetes. Invited Speaker at the Type 1 Diabetes Exchange Investigator meeting. Tampa, FL. April 2015.

Regional

- 2019: Diabetes-Related Technology: More than just apps with the advent of the Artificial Pancreas (AP). Invited Speaker at New England Pharmacists Convention. September 2019. Hartford, CT
- 2017: At Last...Closed Loop Pump Therapy. Invited Speaker Connecticut Alliance of Diabetes Association. Cromwell, CT. November 2017.
- 2017: A Technological Revolution: How academics, industry and hackers have paved the road to closed-loop systems. Grand Rounds Presentation at Mt. Sinai School of Medicine Endocrine Grand Rounds. New York, NY. May 2017
- 2017: A Technological Revolution: How academics, industry and hackers have paved the road to closed loop systems. Invited Speaker JDRF Connecticut and Western Massachusetts Chapter Type One Nation Summit. Hartford, CT April 2017.
- 2017: Update on Diabetes Technologies. Invited Speaker at University of Rochester Annual

- Diabetes Symposium. Rochester, NY. March 2017
- 2017: A Technological Revolution: How academics, industry and hackers have paved the road to closed-loop systems. Invited Speaker at JDRF New England Chapter Speaker Series. Boston, MA. February 2017
- 2015: Assessment of Intranasal Glucagon in Children and Adolescents with Type 1 Diabetes. Invited Speaker Type 1 Diabetes Exchange Investigator meeting. Boston, MA. June 2015
- 2009: The Ins and Outs of Care for the Child with Type 1 Diabetes. Invited Speaker at The Thirty-First Annual School Health Conference Sponsored by the Hezekiah Beardsley Connecticut Chapter of the American Academy of Pediatrics. May 2009.

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale

International/ National

- 2021: **Sherr JL**, Bode BW, Forlenza GP, Laffel LM, Brown SA, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Omnipod 5 in Preschoolers Study Group. Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D) (Oral Presentation). Presented at the annual meeting of the American Diabetes Association, June 2021. Virtual International Meeting.
- 2021: **Sherr JL**, Forlenza G, Buckingham BA, Criego AB, Hansen DW, Bode BW, Brown SA, MacLeish SA, Pinsker JE, DeSalvo DJ, Mehta SN, Laffel LM, Bhargava A, Ly TT, for the Omnipod 5 Research Group. Performance of Omnipod 5 Automated Insulin Delivery System at Specific Targets from 110-150mg/dL over Three Months in Children with Type 1 Diabetes (Oral Presentation). Presented at the annual meeting of the Advanced Diabetes Technologies and Treatments. June 2021. Virtual International Meeting.
- 2020: **Sherr J**. Impact of the MiniMed AHCL System on Post-Prandial glucose after a missed meal bolus in adolescents and adults with Type 1 diabetes. (Oral presentation) Presented at the 10th Annual Diabetes Technology Meeting. November 2020. Virtual National Meeting.
- 2020: **Sherr J**, Schwandt A, Phelan H, Clements MA, Holl RW, Benitez-Aguirre PZ, Miller KM, Woelfle J, Dover T, Maahs DM, Fröhlich-Reiterer E, Craig ME. Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes Over 10 Years Post-Diagnosis from Three Continents. (Poster presentation) Presented at the annual meeting of the American Diabetes Association. June 2020. Chicago, IL. Virtual International Meeting.
- 2020: **Sherr J**, Buckingham BA, Forlenza GP, Galderisi A, Ekhlapour L, Wadwa RP, Zgorski M, Berget C, Kingman RS, Berget C, Lee JB, O'Connor JB, Dumais B, Vienneau T, Huyett LM, Ly TT. Omnipod Personalized MPC algorithm at Target Glucose of 110mg/dL is Safe in Children Aged 2-12 Years without Increasing Hypoglycemia. (Poster presentation) Presented at the annual meeting of the American Diabetes Association. June 2020. Chicago, IL. Virtual International Meeting.
- 2020: **Sherr J**, Buckingham B, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Zgorski M, Kingman R, Berget C, Lee JB, O'Connor J, Dumais B, Vienneau T, Huyett L, Ly T. Performance of Omnipod Personalized Model Predictive Control Algorithm with Multiple Setpoints and Meal and Exercise Challenges in Children with Type 1 Diabetes. (Poster Presentation) Presented at the annual meeting of the Advanced Diabetes Technologies and Treatments. Madrid, Spain, February 2020.
- 2019: **Sherr JL**, Foster NC, Bethin K, Fox LA, Mastrandrea LD, Nathan BM, Redondo MJ, Silverstein J, Simmons J, Clements MA, Tamborlane WV, Thraailkill KM, Wong JC, Wood JR. HbA1c Trajectories from the Time of Diagnosis in Youth with T1D (Poster Presentation) Presented at the annual meeting of the American Diabetes Association. June 2019. San Francisco, CA.
- 2018: **Sherr J**, Forlenza GP, Buckingham B, Peyser TA, Lee JB, O'Connor JB, Dumais B, Huyett LM, Layne J, Ly TT. Safety and Performance of the Omnipod Hybrid Closed Loop System

- in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free Living Conditions. (Poster Presentation) Presented at the annual meeting of American Diabetes Association. June 2018. Orlando, FL.
- 2017: **Sherr J**, DiMeglio L, Kaiserman K, Brazg R, Bailey T, Trygestad J, Slover R, Tsalikian E, Bode B, Christiansen M, Sullivan, Kannard, Jamieson, Cordero T, Shin J, Lee S, Kaufman F. Performance and accuracy of a fourth-generation glucose sensor in a cohort of youth aged 2-18 years with Type 1 Diabetes (T1D). (Poster Presentation) Presented at 43rd Annual ISPAD Conference. October 2017. Innsbruck, Austria.
- 2017: **Sherr J**, Wu M, Foster N, Miller K, Tamborlane WV for the T1DX registry. Schooling diabetes: A Survey of Type 1 Diabetes (T1D) Exchange Registry Participants Describing the Care Provided to Youth with T1D in the School Setting. (Poster Presentation) Presented at 43rd Annual ISPAD Conference. October 2017. Innsbruck, Austria.
- 2017: **Sherr J**, Weinzimer SA, Slover RH, Buckingham BA, Anderson SM, Bailey TS, Bergenstal RM, Bode BW, Brazg R, Garg SK, Ilany J, Shin J, Cordero TL, Kaufman F. Glucose control in adolescents with T1D during the Medtronic hybrid-closed loop pivotal trial. (Oral Presentation) Presented at 10th International Meeting of Pediatric Endocrinology. September 2017. Washington, DC.
- 2017: **Sherr JL**, Wu M, Gal R, Thomas R, Miller K, Tamborlane WV. Learning from the Experts: A Survey of Healthcare Professionals Who Have and Provide Care for Type 1 Diabetes. (Poster Presentation) Presented at Advanced Technologies & Treatments for Diabetes Annual Meeting. February 2017. Paris, France
- 2016: **Sherr JL**, Boyle CT, Miller KM, Beck RW, Tamborlane WV for the T1D Exchange Clinic Network. When school doesn't make a difference: Glycemic control in pediatric participants based on time of year. (Poster Presentation). Presented at the American Diabetes Association. June 2016. New Orleans, Louisiana.
- 2015: **Sherr JL**, Ruedy KJ, Foster NC, Piche CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Schatz DZ, Nathan BM, Marcovina SM, Beck RW, for the Type 1 Diabetes Exchange Intranasal Glucagon Investigators. Glucagon Nasal Powder Delivery System: An Effective Alternative to Intramuscular Glucagon in Youth with Type 1 Diabetes. (Oral presentation) Presented at the European Association for the Study of Diabetes. September 2015. Stockholm, Sweden
- 2015: **Sherr JL**, Ruedy KJ, Foster NC, Piche CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Schatz DZ, Nathan BM, Marcovina SM, Beck RW, for the Type 1 Diabetes Exchange Intranasal Glucagon Investigators. Glucagon Nasal Powder Delivery System: An Effective Alternative to Intramuscular Glucagon in Youth with Type 1 Diabetes. (Poster presentation) Presented at the American Diabetes Association Annula Meeting. June 2015. Boston, MA
- 2015: **Sherr JL**, Michaud C, Patel N, Tichy E, Carria L, Zgorski M, Weyman K, Cengiz E, Tamborlane W, Weinzimer S. Insulin-Sparing Effects and Decreased Post-Prandial Glycemic Excursions with use of Once-Daily Liraglutide while on a Closed Loop System. (Oral Presentation). Presented at the Advanced Technologies & Treatments for Diabetes. February 2015. Paris, France
- 2013: **Sherr JL**, Palau-Collazo MM, Carria LR, Steffen AT, Zgorski M, Weyman K, Tichy E, Michaud C, Cengiz E, Tamborlane WV, Weinzimer SA. Effect of 2-Hr Suspensions of Basal Insulin in Elevating Nighttime Glucose Concentrations. (Poster presentation) Presented at the America Diabetes Association. June 2013 Chicago, IL
- 2013: **Sherr JL**, Palau-Collazo MM, Carria LR, Steffen AT, Zgorski M, Weyman K, Tichy E, Cengiz E, Tamborlane WV, Weinzimer SA. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes (T1D) even in the absence of low glucose. (Poster

- presentation). Presented at the American Society for Clinical Investigation/Association of American Physicians. April 2013. Chicago, IL
- 2013: **Sherr JL**, Palau-Collazo MM, Carria LR, Steffen AT, Zgorski M, Weyman K, Tichy E, Cengiz E, Tamborlane WV, Weinzimer SA. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes (T1D) even in absence of low glucose. (Poster presentations) Presented at the Translational Science Meeting, March 2013. Washington, D.C.
- 2013: **Sherr JL**, Palau-Collazo MM, Carria LR, Steffen AT, Zgorski M, Weyman K, Tichy E, Cengiz E, Tamborlane WV, Weinzimer SA. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes (T1D) even in the absence of low glucose. (Oral presentation) Presented at the Advanced Technologies & Treatments for Diabetes. February 2013. Paris, France
- 2012: **Sherr JL**, Palau-Collazo MM, Carria LR, Steffen AT, Zgorski M, Weyman K, Tichy E, Cengiz E, Tamborlane WV, Weinzimer SA. Safety of nighttime 2-hour suspension of basal insulin in pump-treated type 1 diabetes (T1D) even in the absence of low glucose. (Poster presentation). Presented at the American Diabetes Association, June 2012. Philadelphia, PA
- 2012: **Sherr JL**, Tsalikian E, Fox L, Buckingham B, Weinzimer SA, Tamborlane WV, White NH, Arbelaez AM, Kollman C, Xing D, Ruedy K, for the Diabetes Research in Children Network. Dysregulation of alpha-cell function in youth during the first 2 years of T1D: reciprocal abnormalities in glucagon responses to mixed meal feedings and hypoglycemia. (Oral presentation) Presented at the American Diabetes Association. June 2012. Philadelphia, PA
- 2012: **Sherr JL**, Rink L, Wurtz A, Herold K. Delayed Insulin Secretory Responses are seen in Patients with Long Duration of Diabetes and Residual Insulin. (Poster Presentation) Presented at the Translational Science Meeting. March 2012. Washington, D.C.
- 2011: **Sherr JL**, Tamborlane WV, Tsalikian E, Fox L, Buckingham B, Weinzimer S, White N, Arbelaez AM, Xing D, Ruedy K, Kollman C, Beck R. Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of Type 1 Diabetes. (Poster Presentation) Presented at the San Diego, CA. American Diabetes Association Annual Meeting. June 2011. San Diego, CA.
- 2011: **Sherr JL**, Rink L, Herold K. Delayed Insulin Secretory Responses are seen in Patients with Long Duration of Diabetes and Residual Insulin. (Poster Presentation) Presented at the American Diabetes Association Annual Meeting. June 2011. San Diego, CA.
- 2011: Weinzimer SA, **Sherr JL**, Cengiz E, Palerm CC, Clark B, Kurtz N, Loutseiko M, Roy A, Carria L, Tamborlane WV. Closed-Loop Insulin Delivery Reduces Nocturnal Hypoglycemia During Nights With or Without Antecedent Afternoon Exercise. (Oral Presentation) Presented at the American Diabetes Association Annual Meeting. June 2011. San Diego, CA.
- 2009: **Sherr JL**, Palerm CC, Cengiz E, Clark B, Kurtz N, Loutseiko M, Roy A, Carria L, V Tamborlane WV, Weinzimer SA. Frequency of Exercise-Related Hypoglycemia Using a Closed-Loop Artificial Pancreas: Preliminary Results. (Poster Presentation) Presented at the Ninth Annual Diabetes Technology Meeting. November 2009. San Francisco, CA.

Professional Service

Peer Review Groups/Grants Study Sections

- 2021: National Institutes of Health/ NIDDK, review committee for SBIR RFA
- 2020: National Institutes of Health/ NIDDK, review committee for Diabetes Distress RFA
- 2018: Canadian Institutes of Health Research and the Juvenile Diabetes Research Foundation, review committee for the Strategy for Patient-Oriented Research grants

- 2017: Juvenile Diabetes Research Foundation, Chair for the Metabolic Control & Artificial Pancreas Training grants
- 2016: Stanford University Diabetes Research Center, reviewer for Pilot and Feasibility Grants
- 2016: Juvenile Diabetes Research Foundation, reviewer for Glucose Training and Innovative Grants
- 2015: American Diabetes Association, reviewer for abstracts submitted for consideration in the topic of Pediatric Diabetes
- 2014: Juvenile Diabetes Research Foundation, reviewer for Glucose Training and Innovative Grants

Journal Services

Editorial Board

2019-present *Diabetes Technology and Therapeutics*

Reviewer

2019- present *The New England Journal of Medicine*

2018-present *The Lancet*

2016-present *Journal of the American Medical Association*

2014-present *Journal of Clinical Endocrinology & Metabolism*

2010-present *Diabetes Care*

2010-present *Diabetes, Obesity, and Metabolism*

2009-present *Diabetes Technology and Therapeutics*

Professional Service for Professional Organizations:

American Diabetes Association

2008-present Member, American Diabetes Association

2020-present Appointed to ADA Precision Medicine task force in the area of treatment of type 1 diabetes which is now drafting the second consensus guidelines on precision medicine in the care of diabetes.

2019-present Appointed to ADA/EASD Diabetes Technology Working Group, which is now drafting a position statement on automated insulin delivery

Juvenile Diabetes Research Foundation

2017-2019 Scientific Program Advisory Panel for the Metabolic Control Program of the Juvenile Diabetes Research Foundation. Two-year position to assist with strategic plan of JDRF of this program area.

American Association of Clinical Endocrinologists

2019- present Member, American Association of Clinical Endocrinologists

2019-present Appointed to AACE task force to write consensus guidelines on use of Advanced Diabetes Technologies in Person with Diabetes Mellitus, Co-Chair of the committee with Dr. George Grunberger

Type 1 Diabetes Exchange

2016-2017 Pediatric Junior Faculty Member of the Steering Committee

Society for Pediatric Research

2015-present Member

Endocrine Society

2007-present Member

Pediatric Endocrinology Society

2006- present Member

American Academy of Pediatrics

2003-present Member

Meeting Planning/ Participation

2019-present Endocrine Society Annual Meeting Planning Committee Member

2021-present Appointed to the Diabetes Technology Society Guideline on when and how to monitor ketone levels.

2021-present Appointed to the Advanced Technologies and Treatment of Diabetes Consensus Meeting on Closed-Loop.

Yale University Service

University Committees

2018-2020 Member, Yale Faculty Advisory Council

2013-present Member, Yale Center for Clinical Investigation Science and Safety Committee

Departmental Committees

2021-present Member, Pediatric Pod for Care Center

2014-2020 Abstract Reviewer, Yale Pediatric Research Forum

Hospital Boards & Committees

2012-2016 Yale-New Haven Children's Hospital Interviewer for Residency Applicants

2016-2019 Yale-New Haven Health-System Formulary Integration Committee (FIC) Endocrine Subcommittee

Public Service

2016 Chairperson- JDRF One Walk, New Haven, CT

2014-present Board of Directors, JDRF Greater New Haven Chapter

Bibliography

Peer-Reviewed Original Research

1. **Sherr J**, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. *Nat Clin Pract Endocrinol Metab* 2008; 4: 334-343. PMID: 18446141
2. **Sherr J**, Cengiz E, Tamborlane WV. From pumps to prevention: recent advances in the treatment of type 1 diabetes. *Drug Discovery Today*, 2009; 14: 973-981. PMID: 19580883
3. Ives B, Sikes K, **Sherr JL**, Urban A, Stephenson K, Tamborlane WV. Practical Aspects of Sensor Augmented Pump Therapy with The Medtronic Paradigm Real Time and Guardian Real Time Systems: The Experience of the Yale Children's Diabetes Program. *Infusystems USA* 2009; 6:1-4.
4. Cengiz E, **Sherr JL**, Weinzimer SA, Tamborlane WV. New generation diabetes management: glucose sensor-augmented insulin pump therapy. *Expert Reviews of Medical Devices*. 2011; 8(4): 449-458 PMID: 2172873.
5. Cengiz E, **Sherr JL**, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban A, Tamborlane WV. A Bridge to Insulin Pump Therapy: Twice Daily Regimen with NPH and

- Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. *Endocr Pract* 2011 Nov1; 17(6) 862-6. PMID: 21550949.
6. **Sherr JL** and Weinzimer SW. Diabetes Type 1 and 2 in the Pediatric Population. *Pediatric Annals*. February 2012; 41: e1-e7. PMID: 22299623
 7. Cengiz E, Swan KL, Tamborlane WV, **Sherr JL**, Fredericksen-Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics (PD) when Mixed with Detemir Insulin. *Diabetes Care* 2012; 35(4): 690-692. PMID:22374642
 8. **Sherr JL**, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, and the DirecNet Study Group. Achievement of Target Hemoglobin A1c Levels with Negligible Hypoglycemia and Low Glucose Variability in Youth with Short-term T1D and Residual β -cell Function. *Diabetes Care* 2012;35(4): 817-820. PMID: 22323414
 9. Weinzimer SA, **Sherr JL**, Cengiz E, Kim G, Ruiz JL, Carria L, Voskanyan G, Roy A, Tamborlane WV. Effects of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults with Type 1 Diabetes. *Diabetes Care* 2012 Oct; 35 (10): 1994-9. PMID: 22815298
 10. Ruiz JL, **Sherr JL**, Cengiz E, Carria L, Roy A, Voskanyan G, Tamborlane WV, Weinzimer SA. Effect of insulin feedback on closed-loop glucose control: a crossover study. *J Diabetes Sci and Technol*. 2012 Sep 1; 6 (5) 1123-30. PMID: 23063039.
 11. Cengiz E, **Sherr JL**, Weinzimer SA, Tamborlane WV. Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas. *Expert Rev Med Devices*. 2012; 9(4):315-7. PMID: 22905835
 12. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, **Sherr J**, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. *Diabetologia* 2013; 56(2):391-400. PMID: 23086558
 13. **Sherr J**, Xin Ng D, Ruedy KJ, Beck RW, Kollman C, Buckingham B, White NH, Fox L, Tsalikian E, Weinzimer S, Arbelaez AM, Tamborlane WV, for the Diabetes Research in Children Network. Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth with Short Duration of Type 1 Diabetes. *Diabetes Care* 2013; 36(6): 1470-6. PMID: 2328858.
 14. Cengiz E, Weinzimer SA, **Sherr JL**, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. *Pediatric Diabetes*. 2013; 14(3):168-73. PMID: 23107353.
 15. **Sherr JL**, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. *Diabetes Care* 2013; 36 (10) 2909-14. PMID: 23757427.
 16. Ghazi T, Rink L, **Sherr JL**, Herold KC. Acute metabolic effects of exenatide in patients with Type 1 Diabetes with and without residual insulin to oral and IV glucose challenges. *Diabetes Care*. 2014; 37(1):210-6. PMID: 23939544.
 17. Arbelaez AM, Xing D, Cryer PE, Kollman RW, **Sherr J**, Ruedy KJ, Tamborlane WV, Mauras N, Tsalikian E, Wilson DM, White NH, for the Diabetes Research in Children Network (DirecNet) Study Group. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. *Pediatric Diabetes* 2014 Mar; 15(2):127-34. PMID: 23992543
 18. **Sherr JL**, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual beta-cell function in long-standing type 1 diabetes. *Diabetes Metab Res Rev*. 2014; 30(2):154-62. PMID: 24115337.
 19. **Sherr JL**, Collazo MP, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Tichy E,

- Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump Treated Type 1 Diabetes Even in the Absence of Low Glucose. *Diabetes Care* 2014; 37 (3):773-9. PMID: 24170766.
20. Cengiz E, Weinzimer SA, **Sherr JL**, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming. *Diabetes Technol Ther.* 2014; 16 (1):20-5. PMID: 24367934
 21. **Sherr JL**, Tsalikian E, Fox L, Buckingham B, Weinzimer S, Tamborlane WV, White N, Arbelaez A, Kollman C, Xing D, Ruedy K, for the Diabetes Research in Children Network (DirecNet) Study Group. Evolution of abnormal plasma glucagon responses to mixed meal feedings in youth with type 1 diabetes during the first two years following diagnosis. *Diabetes Care* 2014; 37 (6):1741-1744. PMID: 24696460.
 22. **Sherr JL**, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen T, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT. Use of insulin pump therapy in youth with type 1 diabetes and its impact on metabolic control: Comparison of results from the three large, trans-Atlantic paediatric registries. *Diabetologia.* 2016 Jan- 59 (1): 87-91. PMID: 26546085
 23. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, **Sherr JL**, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Intranasal glucagon for treatment of insulin induced hypoglycemia in adults with type 1 diabetes: A randomized, cross-over non-inferiority study. *Diabetes Care.*2016 Feb; 39(2):264-70. PMID: 26681725
 24. **Sherr JL**, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Beck RW. Glucagon nasal powder: An effective alternative to intramuscular glucagon in youth with type 1 diabetes. *Diabetes Care.* 2016 April 39 (4):555-62. PMID: 26884472
 25. Ly TT, Weinzimer SA, Maahs DM, **Sherr JL**, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. *Pediatric Diabetes.* Epub May 2016. PMID: 27191182
 26. **Sherr JL**, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin Sparing Manner during Closed-Loop Insulin Delivery: The beneficial effects of adjunctive pramlintide and liraglutide. *Diabetes Care.* 2016 Jul 39 (7)1127-34. PMID: 27208332
 27. Rickels MR, Ruedy KJ, Foster NC, Piche C, Dulude H, **Sherr JL**, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck TW; T1D Exchange Intranasal Glucagon Investigators. Response to Comment on Rickets et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized, cross-over non-inferiority study. *Diabetes Care.*2016 Oct 39 (10)e193-4. PMID: 27660135.
 28. **Sherr JL**, Boyle CT, Miller KM, Beck RW, Tamborlane WV; T1D Exchange Clinic Network. No Summer Vacation from Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year. *Diabetes Care.* 2016 Oct 4. PMID:27703027
 29. Patel NS, VanName MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, **Sherr JL**. Mitigating reductions in glucose during exercise on closed-loop insulin delivery: The Ex-Snacks Study. *Diabetes Technology & Therapeutics.* 2016 Dec; 18 (12):794-799. PMID: 27996320
 30. Erie C, VanName M, Weyman K, Weinzimer SA, Finnegan J, Sikes K, Tamborlane WV, Sherr JL. Schooling Diabetes: Use of CGM and Remote Monitors in the Home and School Settings. *Pediatric Diabetes.* 2018. 19 (1): 92-97. PMID: 28303678

31. Haymond MW, Dubose SN, Rickels MR, Wolpert H, Shah VN, **Sherr JL**, Weinstock R, Agarwal S, Verdejo AS, Cummins MJ, Newswanger B, Beck RW; T1D Exchange Mini-Dose Glucagon Study Group. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Non-Severe Hypoglycemia in Adults with Type 1 Diabetes. *J Clin Endocrinol Metab* 2017 102 (8): 2994-3001. PMID: 28591776
32. Messer L, Forlenza GP, Wadwa RP, **Weinzimer SA, Sherr JL**, Hood KK, Buckingham BA, Slover RH, Maahs DM. The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration. *Pediatric Diabetes* 2018; 19 (1): 14-17. PMID: 28656656.
33. Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, **Sherr JL**. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT-2 inhibitor: an insulin pump suspension study. *Diabetes Technology and Therapeutics*. 2017; 19 (11):618-622. PMID: 29068709
34. Galderisi A, **Sherr JL**, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane WV. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated glucagon Responses in Type 1 Diabetes. *JCEM* 2018 103 (3):1088-1094. PMID: 29211871.
35. Messer LH, Forlenza GP, **Sherr JL**, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed670G system. *Diabetes Care*. 2018; 41(4): 789-796. PMID: 29444895
36. DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, Lilenthal E, **Sherr JL**, Tauschmann M, Holl RW; T1D Exchange and DPV Registries. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. *Pediatr Diabetes*. 2018 Jun 20. PMID: 29923262
37. Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey Ts, Brazg R, Christiansen MP, **Sherr JL**, Tsalikian E, Kaiserman KB, Sullivan A, Huang S, Shin J, Lee SW, Kaufman F. *Diabetes Technol Ther*. 2018; 20 (9):576-584. PMID: 30063162
38. Shah VN, Wu M, Polsky S, Snell-Bergeon JK, **Sherr JL**, Cengiz E, DiMeglio LA, Pop-Busui R, Mizokami-Stout K, Foster NC, Beck RW; for the T1D Exchange Clinic Registry. Gender Differences in Diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. *J Diabetes Complications* 2018; 32 (10):961-965. PMID: 30121205.
39. Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, **Sherr JL**. Reversal of Ketosis in Type 1 Diabetes is Not Adversely Affected by SGLT2 Inhibitor Therapy. *Diabetes Technol Ther* 2019 Mar 21 (3):101-104. PMID: 30688521
40. Elahi S, Patel AD, Guandalini C, Steffen A, **Sherr J**, Tamborlane WV, VanName MA. Impact of Switching Youth with Diabetes to Insulin Degludec in Clinical Practice. *Endocr Pract* 2019 Mar; 25(3):226-229. PMID: 30913005
41. Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Bendrame F, Bergenstal R, Tamborlane WV, Watson SE, **Sherr J**. Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Participants: A Multicenter Prospective Study. *JCEM* 2019 Apr 25. PMID: 31127824
42. Galderisi A, **Sherr JL**. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. *Pediatr Ann*. 2019 Aug 1: 48:e311-e318. PMID: 31426099.
43. **Sherr JL**, Buckingham BA, Forlenza GP, Galdersisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed Loop System in Adults, Adolescents and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. *Diabetes Technol Ther*. 2020 Mar; 22 (3) :174-184. PMID: 31596130.
44. Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeua KJ, Hao W, Clements MA, **Sherr JL**, Pratley RE, Hannon TS, Shah VN, Miller KM, Greenbaum CJ, T1D Exchange Beta-Cell Function Study Group. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. *J Clin Invest* 2020 Mar3. PMID: 31895699

45. Shah VN, Bailey R, Wu M, Foster NC, Pop-Bussui R, Katz M, Crandall J, Bacha F, Nadeau K, Libman I, Hiers P, Mizokami-Stout K, DiMeglio LA, **Sherr J**, Pratley R, Agarwal S, Snell-Bergoeon J, Cengiz E, Polsky S, Mehta SN. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from a Prospective Real-life T1D Exchange Registry. *J Clin Endocrinol Metab.* 2020 May 1; 105 (5). PMID: 31955209
46. DuBose SN, Li Z, **Sherr JL**, Beck RW, Tamborlane WV, Shah VN. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. *J Diabetes Sci Technol.* 2020 Feb 17. PMID: 32064911
47. Suico JG, Hovelmann U, Zhang S, Shen T, Bergman B, **Sherr J**, Zijlstra E, Frier BM, Plum-Morschel L. Glucagon Administration by Nasal and Intramuscular Routes in Adults with Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. *Diabetes Ther.* 2020 Jul; 11(7): 1591-1603. PMID: 32514794
48. Laffel LM, Kanapka LG, Beck RW, Bergamo K, Clements MA, Criego A, DeSalvo DJ, Goland R, Hood K, Liljenquist D, Messer LH, Monzavi R, Mouse TJ, Prahalad P, **Sherr J**, Simmons JH, Wadwa RP, Weinstock RS, Willi SM, Miller KM; CGM Intervention in Teens and Young Adults with T1D (CITY) Study Group; CDE10. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults with Type 1 Diabetes: A Randomized Clinical Trial. *JAMA.* 2020 Jun 16; 323 (23): 2388-2396. PMID: 32543683.
49. Levy CJ, Foster NC, DuBose SN, Agarwal S, Lysons SK, Peters AL, Uwaifo GI, DiMeglio LA, **Sherr JL**, Polsky S. Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange. *J Diabetes Sci Technol.* 2020 Nov 2: 1932296820972123. doi: 10.1177/1932296820972123. Online ahead of print. PMID: 33218278
50. Polsky S, Foster NC, DuBose SN, Agarwal S, Lyons S, Peters AL, Uwaifo GI, DiMeglio LA, **Sherr JL**, Levy CJ. Incident diabetes complications among women with type 1 diabetes based on parity. *J Matern Fetal Neonatal Med.* 2020 Dec 6:1-6. doi: 10.1080/14767058.2020.1858278. Online ahead of print. PMID: 33280471
51. **Sherr JL**, Schwandt A, Phelan H, Clements MA, Holl RW, Benitez-Aguirre PZ, Miller KM, Woelfle J, Dover T, Maahs DM, Frohlich-Reiter E, Craig ME. HemoglobinA1c Patterns of Youth with Type 1 Diabetes 10 Years Post-Diagnosis from 3 Continents. *Pediatrics.* 2021 Jul 27: e2020048942. Online ahead of print. PMID: 34315809.
52. Brown SA, Forlenza GP, Bode BW, Pinsky JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, **Sherr JL**, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT, for the Omnipod 5 Research Group. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System with Customizable Glycemic Targets in Pediatric and Adult Participants with Type 1 Diabetes. *Diabetes Care.* Jun7;dc210172. PMID: 34099518
53. Nally LM, Wagner J, **Sherr J**, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. *Endocr Pract.* 2021 Jun; 27 (6): 545-551. PMID: 34120699

Chapters, Books, and Reviews

54. **Sherr, J**, Tamborlane WV, Bode B. “Chapter 27: Insulin Pump Therapy” *Therapy for Diabetes Mellitus and Related Disorders, 5th Edition.* Ed. Harold Lebovitz. American Diabetes Association, 2009. 322-331.
55. **Sherr JL**, Cengiz E, VanName MA, Weinzimer SA, Tamborlane WV. “Future drug treatment for type 1 diabetes.” *Textbook of Diabetes, 5th Edition.* Ed. Richard Holt, Allan Flyvberg, Barry Goldstein, and Clive Cockram, Wiley-Blackwell. 2016.
56. Ang K, **Sherr JL**. Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. *Expert Opinion on Drug Delivery.* 2017; 14 (9):1113-1131.

PMID: 28774208.

57. **Sherr JL.** Closing the Loop on Managing Youth with Type 1 Diabetes: Children are Not Just Small Adults. *Diabetes Care.* 2018 Jun 23. PMID: 29936422
58. Nally LM, **Sherr JL**, VanName M, Patel A, Tamborlane WVT. Pharmacologic treatment options for type 1 diabetes: what's new? *Expert Rev Clin Pharmacol.* 2019 May; 12(5) 471-479. PMID 30892094
59. **Sherr JL.** From Purified Pork to Pumps: How Technology has changed my life with diabetes. *Diabetes Technology: Science and Practice, 1st Edition.* Ed. Boris Drazin. American Diabetes Association, 2019.
60. Perkins BA, **Sherr JL**, Mathieu C. Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. *Science* 2021 Jul 30; 373 (6554): 522-527. PMID 34326234

Invited Editorial and Commentaries

61. Tamborlane WV, **Sherr JL.** Diabetes: insulin pumps in children with T1DM- we told you so. *Nat Rev Endocrinol.* 2013; 9(11): 629-30. PMID: 24080733.
62. **Sherr JL.** Expert Commentary on Risk factors Associated with Mortality During Early Adulthood in Type 1 Diabetes. *Practice Update.* December 2014. (<https://www.practiceupdate.com/content/risk-factors-associated-with-mortality-during-early-adulthood-in-type-1-diabetes/19710/62>)
63. **Sherr JL.** Expert Commentary on Intranasal Glucagon for Insulin-Induced Hypoglycemia in Type 1 diabetes. *Practice Update.* January 2016. (<https://www.practiceupdate.com/content/intranasal-glucagon-for-insulin-induced-hypoglycemia-in-type-1-diabetes/33703/62>).
64. **Sherr JL.** Expert Commentary on Improved Glycemic Control with Closed-Loop Insulin in Pregnant Diabetic Women. *Practice Update.* August 2016 (<https://www.practiceupdate.com/content/improved-glycemic-control-with-closed-loop-insulin-in-pregnant-diabetic-women/43138/62>).
65. **Sherr JL.** Expert Commentary on Insulin Infusion and Glucose Monitoring: A Guideline for Diabetes Technology. *Practice Update.* September 2016 (<https://www.practiceupdate.com/content/insulin-infusion-and-glucose-monitoring-a-guideline-for-diabetes-technologies/43658/62>).
66. **Sherr JL.** Expert Commentary on Fixed-Dose Coadministration of Pramlintide Plus Regular Insulin Shows Promise for Postprandial Hyperglycemia. September 2018 (<https://www.practiceupdate.com/content/fixed-dose-coadministration-of-pramlintide-plus-regular-insulin-shows-promise-for-postprandial-hyperglycemia/73370/62>)
67. Galderisi A, **Sherr JL.** Enlarging the loop: closed-loop insulin delivery for type 1 diabetes. *Lancet.* 2018; 392 (10155)1282-1284. PMID: 30292579
68. Connecting the Dots: Validation of Time in Range Metrics with Microvascular Outcomes. Hirsch IB, **Sherr JL**, Hood KK. *Diabetes Care* 2019 Mar; 42 (3):345-348. PMID: 30787056

Practice Guidelines, Standards and Consensus Statements

69. **Sherr JL**, Tauschmann M, Battelino T, De Bock M, Forlenza G, Roman R, Hood KK, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018. *Diabetes Technologies. Pediatric Diabetes.* 2018; 19 (Supplement 27): 302-325. PMID: 30039513.
70. Grunberger G*, **Sherr JL***, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J. American Association of Clinical Endocrinology Clinical Practice Guideline: Use of Advanced Technology in Management of Persons with Diabetes Mellitus. *Endocrine Practice.* 2021 Jun; 27(6): 505-537. PMID: 34116789

Case Reports, Technical Notes, Letters

71. Jastreboff, A, **Sherr J**. Three faces of hypothalamic tumors. *J Pediatr Endocrinol Metab* 2007; 20:471.
72. **Sherr J**, Lord K, Tamborlane WV, Weinzimer SA. Case 15-year-old boy with confusion: A teenager is brought for evaluation after waking with altered mental status. *Contemporary Pediatrics* May 2010.